Theravance Biopharma R&d Ip, LLC

Theravance, Inc.

Gilead Sciences, Inc.

Pliant Therapeutics, Inc.

Lan Jiang

Daniel D Long

John R Jacobsen

Paul Ross Fatheree

Hong Yang

Daisuke Roland Saito

Hang Chu

Michael L Mitchell

David W Lin

Anna E Hurtley

Devan Naduthambi

Priscilla M Van Dyke

Seok-Ki Choi

Robert Murray McKinnell

Daniel Marquess

Jiayao Li

Lori Jean Van Orden

Ana Zurisadai Gonzalez Buenrostro

Qiaoyin Wu

Xiaochun Han

Gregg M Schwarzwalder

Hui Li

David John Morgans, Jr

Jacob Cha

Timothy Hom

William John Watkins

Roland Gendron

Chandrasekar Venkataramani

Adam Aaron Goldblum

Jennifer R Zhang

Darryl Kato

Juan A Guerrero

Tetsuya Kobayashi

Hongyan Guo

Jonathan William Medley

Vickie H Tsui

Gustave Bergnes

Randall Halcomb

Timothy J Church

Ioanna Stergiades

Devleena M Shivakumar

Matthew J Von Bargen

Melissa Fleury

Scott E Lazerwith

Xiaofen Li

S Derek Turner

Cameron Smith

Anne-Marie Beausoleil

Bryan A Frieman

Neil H Squires

Steven D E Sullivan

John Edward Knox, Jr

Mandy Loo

Gavin Ogawa

Kassandra Lepack

Tae H Hwang

Zachary Newby

Hyung-Jung Pyun

Scott D Schroeder

Venkat R Thalladi

Gary E L Brandt

Nathan D Shapiro

Marta Dabros

Suzanne M Szewczyk

Katerina Leftheris

Michael Robert Leadbetter

Eric L Stangeland

Sheila M Zipfel

Yajun Zheng

Sabine Axt

Sean Gary Trapp

Chengguo Dong

Maureen Kay Reilly

Jerry Nzerem

Qingming Zhu

Manuel Munoz

Chun Chen

Patrick Andre

Ezra Roberts

Gregg M Schwarzwälder

Miroslav Rapta

Pierre-Jean Colson

Sean Dalziel

Weijiang Zhang

Xiaojun Huang

Leticia Maria Preza

Gene Timothy Fass

Hao Zhang

Gary Brandt

Noah M Benjamin

Christopher Bailey

Kirsten M Phizackerley

Tmothy J Church

Darren Finklestein

Robert Murray Mckinnell

Steven De Sullivan

Gary El Brandt

Sean M Dalziel

John E Knox

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Amino acid compounds and methods of use

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure generally relates to compounds of Formula (1) and pharmaceutical compositions that may be used in methods of treating cancer.

MCL1 inhibitors

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Substituted pyridotriazine compounds and uses thereof

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

MCL-1 inhibitors

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Tetracyclic compounds and uses thereof

The present disclosure relates generally to compounds, of Formula I Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Bridged tricyclic carbamoylpyridone compounds and uses thereof

The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK kinase inhibitor compounds for treatment of respiratory disease

The invention relates to compounds of formula (I): or a salt thereof, wherein R, A, L, and Rand n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;1 integrin inhibitors that are useful for treating tissue specific fibrosis.

N-acyl amino acid compounds and methods of use

The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer. 

The invention relates to compounds of formula (I): or a salt thereof, wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Growing community of inventors

Foster City, CA, United States of America

Lan Jiang